Case Report

Spontaneous regression of angiolymphoid hyperplasia with eosinophilia (AHLE): A case report

Yasmine Slimani a,*, Fouzia Hali a, Cheikh Sid’Ahmed Tolba b, Farida Marnissi b, Soumiya Chiheb a

a Department of Dermatology and Venerology, Ibn Rochd University Hospital, Casablanca, Morocco
b Department of Pathology, Ibn Rochd University Hospital, Casablanca, Morocco

ARTICLE INFO

Keywords: Angiolymphoid hyperplasia with eosinophilia AHLE Vascular tumor

ABSTRACT

Introduction: and importance - Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare benign microvascular proliferation. It is clinically characterized by intradermal or subcutaneous papules and/or nodules. Treatment consists mainly of surgery or laser therapy, with a high recurrence rate. Spontaneous regression is rare but possible.

Case presentation: A 72-year-old man presented for an erythematous plaque on his scalp. Physical examination demonstrated a large angiomatous indurated subcutaneous plaque. The lesion was not pulsatile. The doppler ultrasound revealed no underlying vascular malformation. The biopsy revealed an ALHE. No further treatment was carried out. During the follow-up, the lesion gradually subsided. After one-year follow-up, the lesion had regressed with no sign of recurrence.

Clinical discussion: There are different treatment modalities for AHLE management, including surgical excision, cryotherapy and lasers. However, none of these modalities has provided consistent results and recurrence after treatment is common.). Rare instances of spontaneous regression have been reported.

Conclusion: Given the rarity of cases of spontaneous resolution, ALHE may be considered as a chronic condition, especially since recurrences are frequent. A “wait and see” approach can be proposed in some specific situations.

1. Background

Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare benign microvascular proliferation tumor of unknown etiology tumor [1]. It presents as red to brown papules or nodules, located in the head and neck region, especially around the ears and on the scalp. Microscopically, ALHE consists of plumped epithelioid or histiocytoid endothelial cells and accompanying eosinophils and lymphocytes. Treatment consists mainly of surgery or laser therapy. Recurrence after treatment is common [2]. Spontaneous regression is rare but possible. We report a case of spontaneous regression of ALHE after two-years follow-up. The work has been reported in line with the SCARE 2020 criteria [3].

2. Case report

A 72-year-old man, with no significant past medical history, was referred to our department for evaluation of a rapidly enlarging, mildly itchy erythematous plaque on his scalp. The lesion had first been noticed 6 months ago. There was no known traumatic event, but bleeding after minor frictional trauma was reported by the patient. Physical examination demonstrated a large angiomatous indurated subcutaneous plaque, located on the occipital region of the scalp (Fig. 1). The lesion was not pulsatile. There was no regional lymph node enlargement. Laboratorv findings revealed no peripheral eosinophilia. Prior to biopsy, our differential diagnosis were ALHE, Kimura disease, lymphoma cutis, angiosarcoma, metastatic tumor and sarcoidosis. The doppler ultrasound revealed no underlying vascular malformation. The biopsy revealed vascular hyperplasia with epithelioid endothelial cells, as well as lymphocytic and eosinophilic infiltrate with a few plasma cells and rare giant cells. No atypical mitotic figures were observed (Figs. 2 and 3). The diagnosis of ALHE was confirmed by clinical presentation and histology. No further treatment was carried out (either local or systemic corticosteroid administration, or excision) because the patient lacked any disabling symptoms and he did not prefer such treatment. During
the follow-up, the lesion gradually subsided. After one-year follow-up, the lesion had regressed with no sign of recurrence (Fig. 4).

3. Discussion

Both the cell of origin and the pathogenesis of ALHE remain controversial. The World Health Organization (WHO) and the International Society for the Study of Vascular Anomalies (ISSVA) classify ALHE as a benign vascular tumor [4]. However, this lesion has several features that imply a significant reactive, as opposed to neoplastic, component.
Furthermore, ALHE or a subset of ALHE cases harboring a clonal T-cell population have been reported and may represent a T-cell lymphoproliferative disorder of a benign or low-grade malignant nature [5]. ALHE occurs in young to middle-aged adults without gender or ethnic predilection. Previous reports of a female predominance are not supported by more recent series, including our case report [6].

Past reports emphasized pruritus as the most common symptom associated with ALHE, as in our patient. Pain is as an uncommon symptom. Spontaneous bleeding over the lesion in our patient is consistent with the vascular nature of the lesion (7).

The clinical lesions appear as single or multiple red-brown papules or as subcutaneous nodules with a predilection for the head and neck region. ALHE is characterized histologically by proliferations of capillary-sized vessels with epithelioid endothelial cells surrounding larger thick-walled vessels, accompanied by eosinophils and lymphocytes. The differential diagnosis of ALHE includes Kimura’s disease, angiomatous lymphoid hamartoma, hemangioma, pyogenic granuloma, Kaposis sarcoma, lymphoma, and epithelioid hemangioendothelioma. Unlike Kimura’s disease, peripheral eosinophilia is inconstant [8]. It was absent in our patient. There are different treatment modalities including surgical excision, cryotherapy, chemotherapy, intralesional and systemic corticosteroids, curettage, electrodeexcision, radiation, and lasers. However, none of these modalities has provided consistent results and recurrence after treatment is common (9).

According to the literature, cases of ALHE with earlier age of onset, longer duration, and multiple lesions are linked to higher recurrence rates [6]. Rare instances of spontaneous regression have been reported (Table 1). On 1969, Wells and Whimster published the first report describing 9 cases of ALHE characterized by marked vascular proliferation with infiltration of eosinophils. One of them, a 23-year-old man, had a nodule for 3 months in the left nasolacrimal region that was excised. One year later, a nodule recurrence was found but no further treatment was carried out. Follow up after 4 years showed that there was no longer any nodule at the original site and no fresh lesion [8]. In a study of 116 cases of ALHE, Olsen et al. reported spontaneous resolution without any form of therapy in 2 patients [7]. Fays et al. described the case of a 32-year-old male patient having five angiomatous lesions of the face consistent with ALHE, that showed spontaneous regression with no recurrence after three years follow-up [10]. Given the rarity of cases of spontaneous resolution, ALHE may be considered as a chronic condition, especially since recurrences are frequent. Together with previously published reports, the case presented here suggests that in some specific situations, a “wait and see” approach with close monitoring can be proposed to patients suffering from ALHE as a first step.

### Provenance and peer review

Not commissioned, externally peer-reviewed.

### Conflicts of interest

None.

| Author          | Number of patients | Age   | Findings                                                                 | Follow-up     |
|-----------------|--------------------|-------|--------------------------------------------------------------------------|---------------|
| Wells et al.    | 1                  | 23    | Recurrence of an ALHE of the left nasolacrimal region that was excised the year before | 4 years       |
| Olsen et al.    | 2                  | Not precised | Not precised                                                                 | Not precised |
| Fays et al.     | 1                  | 32    | Five angiomatous lesions of the face                                      | 3 years       |

### Ethics approval

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

### Guarantor

I, Yasmine Slimani, corresponding author of the manuscript, accept full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

### Please state any conflicts of interest

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

### Please state any sources of funding for your research

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient’s guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: “Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request”.

Patients have a right to privacy. Patients’ and volunteers’ names,
initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.

Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Written informed consent was obtained from the patient’s parent for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contribution

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.

• Drafting of the manuscript: Yasmine Slimani
• Examination of the biopsy: Cheikh Sid’Ahmed Tolba, Farida Marnissi
• Critical revision of the manuscript for important intellectual content: Fouzia Hali, Soumiya Chiheb

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.

You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

1. Name of the registry:
2. Unique Identifying number or registration ID:
3. Hyperlink to your specific registration (must be publicly accessible and will be checked):

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

Funding sources

None.

Declaration of competing interest

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2021.102376.

References

[1] C.D.M. Fletcher, J.A. Bridge, P.C.W. Hogendoorn, F. Mertens, WHO classification of soft tissue tumours, in: WHO Classification of Tumours of Soft Tissue and Bone, fourth ed., IARC Press, Lyon, 2013, p. 11.
[2] R. Guo, A.C. Gavino, Angiolymphoid hyperplasia with eosinophilia, Arch. Pathol. Lab Med. 139 (5) (2015) 683–686.
[3] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, for the SCARE Group, The SCARE 2020 guideline: updating consensus surgical Case Report (SCARE) guidelines, Int. J. Surg. 84 (2020) 226–230.
[4] M. Wassef, F. Blei, D. Adams, et al., Vascular Anomalies classification: recommendations from the international society for the study of vascular Anomalies, Pediatrics 136 (2015) 203–214.
[5] W. Kempf, A.C. Haeffner, K. Zepter, et al., Angiolymphoid hyperplasia with eosinophilia: evidence for a T-cell lymphoproliferative origin, Hum. Pathol. 33 (10) (2002 Oct) 1023–1029.
[6] B.L. Adler, A.E. Krausz, A. Minuti, J.I. Silverberg, H. Lev-Tov, Epidemiology and treatment of angiolymphoid hyperplasia with eosinophilia (ALHE): a systematic review, J Am Acad Dermatol. mar 74 (3) (2016) 506–512.
[7] T.G. Olsen, E.B. Helwig, Angiolymphoid hyperplasia with eosinophilia. A clinicopathologic study of 116 patients, J. Am. Acad. Dermatol. 12 (1985) 781–796.
[8] S.I. Chun, H.G. Ji, Kinmura’s disease and angiolymphoid hyperplasia with eosinophilia: clinical and histopathologic differences, J. Am. Acad. Dermatol. 27 (6Pt1) (1992) 954–958.
[9] S.A. Tambe, C.S. Nayak, Successful management of angiolymphoid hyperplasia with eosinophilia by radiofrequency, J. Cutan. Aesthetic Surg. 10 (2) (2017 Apr-Jun) 116–118.
[10] Ségolene Fays, Maladie de Kimura et hyperplasie angiolymphoïde avec eosinophile: similitudes et critères distinctifs à propos de 2 cas, Sciences du Vivant [q-bio, 2003 ffhal-01733182f.]